Oculis’ (OCS) Stock Moves Sideways Amid Growing Anticipation
PremiumMarket NewsOculis’ (OCS) Stock Moves Sideways Amid Growing Anticipation
3M ago
Oculis price target lowered to $20 from $21 at BofA
Premium
The Fly
Oculis price target lowered to $20 from $21 at BofA
5M ago
Oculis price target raised to $30 from $28 at H.C. Wainwright
Premium
The Fly
Oculis price target raised to $30 from $28 at H.C. Wainwright
5M ago
Oculis announces listing on Nasdaq Iceland Main Market
PremiumThe FlyOculis announces listing on Nasdaq Iceland Main Market
7M ago
Oculis names Dr. Snehal Shah as President of Research & Development
Premium
The Fly
Oculis names Dr. Snehal Shah as President of Research & Development
7M ago
Oculis announces ‘positive’ results from Phase 3 OPTIMIZE-1 trial of OCS-01
Premium
The Fly
Oculis announces ‘positive’ results from Phase 3 OPTIMIZE-1 trial of OCS-01
7M ago
Oculis provides update on progress of its late-stage clinical trials
PremiumThe FlyOculis provides update on progress of its late-stage clinical trials
8M ago
Chardan lays out top 4 biotech picks for 2024
Premium
The Fly
Chardan lays out top 4 biotech picks for 2024
9M ago
Oculis initiates second trial in ocular inflammation, pain, says H.C. Wainwright
Premium
The Fly
Oculis initiates second trial in ocular inflammation, pain, says H.C. Wainwright
11M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100